Navigation Links
Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
Date:2/11/2011

SAN ANTONIO, Feb. 11, 2011 /PRNewswire/ -- Aperion Biologics, Inc. announced the enrollment and implantation of the first patients in the Company's clinical trial of its Z-Lig™ Anterior Cruciate Ligament Reconstruction (ACLR) Device for the treatment of ligament injuries of the knee.  The primary objective of the multicenter study is to provide additional evidence of the safety and performance of Z-Lig in the reconstruction of patients' knees with primary ACL ruptures.  Seven sites in Europe and one site in South Africa are participating in this clinical trial.  Dr. Willem van der Merwe of the Sports Science Orthopaedic Clinic in Cape Town, South Africa said, "We are pleased to be part of this cutting-edge study.  Graft options are limited for ligament reconstruction procedures and Z-Lig could prove to be a tissue alternative which would enhance the world of ACL reconstruction surgeries."  The study results will be used to support regulatory approvals and clinical acceptance of the Z-Lig ACLR device in select markets outside of the United States.

"Initiating the Z-Lig ACLR clinical trial is an important step not only for our technology and the Company but also for the field of orthopaedics," said Daniel R. Lee, Aperion Biologics' CEO.  "Z-Lig ACLR represents an opportunity to provide a biologic graft sourced from non-human tissue.  This device is a functional scaffold which supports the regeneration of the patient's own tissue.  It has been a long-standing goal for surgeons and the industry globally to have a readily available, off-the-shelf ACL graft."

The ACL is the most commonly injured knee ligament.  Over 800,000 knee ligament reconstruction surgeries are estimated to be performed each year worldwide.

Further information on the Z-Lig study is also available on www.ClinicalTrials.gov.

About  Z-Lig

Aperion's Z-Lig is a p
'/>"/>

SOURCE Aperion Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
2. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
3. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
4. Reportlinker Adds Immunogenicity to Biologics
5. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
6. Crescendo Biologics Announces First Triple Knockout Mouse
7. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
8. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
9. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
10. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
11. Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... to manufacture proteins including biosimilar therapeutics, today provided ... the second quarter ended June 30, 2014. ... public offering, we have the capital to continue ... our proprietary protein expression platform," stated Bertrand C. ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... University of the Negev,s Prof. Ron Folman has been named as ... Laser Science and Quantum Optics. The award is presented ... in honor of Willis E. Lamb Jr., who was the 1955 ... physicist and a member of BGU,s Ilse Katz Institute for Nanoscale ...
... Reportlinker.com announces that a new market research report ... Biomarkers - technologies,markets and companies ... This report follows the broad definition of a ... and evaluated as an indicator of normal biological or ...
... NEW YORK, Nov. 9, 2010 NeoStem, Inc. (NYSE Amex: ... biopharmaceutical company with operations in the U.S. and China, today ... M.D., MBA, will be honored tonight at Moves Magazine,s 2010 ... at the Astor Center, 399 Lafayette Street, New York City. ...
Cached Biology Technology:Reportlinker Adds Biomarkers - Technologies, Markets And Companies 2Reportlinker Adds Biomarkers - Technologies, Markets And Companies 3Reportlinker Adds Biomarkers - Technologies, Markets And Companies 4Reportlinker Adds Biomarkers - Technologies, Markets And Companies 5Reportlinker Adds Biomarkers - Technologies, Markets And Companies 6Reportlinker Adds Biomarkers - Technologies, Markets And Companies 7Reportlinker Adds Biomarkers - Technologies, Markets And Companies 8Reportlinker Adds Biomarkers - Technologies, Markets And Companies 9Reportlinker Adds Biomarkers - Technologies, Markets And Companies 10Reportlinker Adds Biomarkers - Technologies, Markets And Companies 11Reportlinker Adds Biomarkers - Technologies, Markets And Companies 12Reportlinker Adds Biomarkers - Technologies, Markets And Companies 13Reportlinker Adds Biomarkers - Technologies, Markets And Companies 14Reportlinker Adds Biomarkers - Technologies, Markets And Companies 15Reportlinker Adds Biomarkers - Technologies, Markets And Companies 16Reportlinker Adds Biomarkers - Technologies, Markets And Companies 17Reportlinker Adds Biomarkers - Technologies, Markets And Companies 18Reportlinker Adds Biomarkers - Technologies, Markets And Companies 19Reportlinker Adds Biomarkers - Technologies, Markets And Companies 20NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards 2
(Date:8/29/2014)... have made some surprising discoveries about the body,s ... virus (SIV), the team found that specialized cells ... responders to viral invasion and are the source ... interleukin-1 beta (IL-1β). , Though aimed at ... the gut epithelium that provides a barrier to ...
(Date:8/29/2014)... U.S. Ebola researcher from the University of Texas Medical Branch ... of three monoclonal antibodies can completely protect monkeys against a ... infection, at a time when the disease is severe. , ... editorial for Nature discussing advances in Ebola treatment ... are among the most deadly of pathogens, with fatality rates ...
(Date:8/29/2014)... German . ... nitrogen cycle on Earth and in biological wastewater treatment ... depend on nitrite as their source of energy. An ... microbiologist at the University of Vienna, has now shown ... source of energy. The oxidation of hydrogen with oxygen ...
Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
... Calif. How much calcium could a hibernating woodchuck,s ... could sequester calcium? More than enough, it turns out, ... heart rhythms such as ventricular tachycardia and ventricular fibrillation ... to a new study of the hibernating animals that ...
... eluded vaccine-makers for thirty years, in part due to ... clinical virologists from the Massachusetts Institute of Technology (MIT) ... a promising strategy for vaccine design using a mathematical ... to quantum physics, as well as in analyses of ...
... restaurant menus might meet federal labeling requirements but don,t do ... meal choices, a new Columbia University School of Nursing (CUSON) ... NP, DNSc, assistant professor of nursing at CUSON, and colleagues, ... Journal of Urban Health . The researchers studied the calorie ...
Cached Biology News:Woodchucks and sudden cardiac death 2Vaccines for HIV: A new design strategy 2Fast-food menu calorie counts legally compliant but not as helpful to consumers as they should be 2Fast-food menu calorie counts legally compliant but not as helpful to consumers as they should be 3
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Mycoplasma and virus tested...
... MagicMark XP Western Protein Standards are ... protein molecular weight estimation directly on ... an IgG binding site, allowing direct ... used to detect your target protein ...
... Clone/PAD: 3F10B10. Immunogen: Synthetic ... region of JAB1 (Jun activation ... Specificity: Specific for the JAB1 ... controls: 293T Jurkat cell lysates). ...
Biology Products: